Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer

NCT00298688 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00298688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00298688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2004
Completion date
March 31, 2007
Enrollment
56
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer